Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.878%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tarsis Collaboration with Crop-Protection Company

16 Jul 2018 07:00

RNS Number : 6299U
Frontier IP Group plc
16 July 2018
 

 

 

Released : 16 July 2018 07.00am

Frontier IP Group plc

16 July 2018

 

RNS REACH / RNS

AIM: FIPP

16 July 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Tarsis Technology Collaboration with World-leading Crop-Protection Company

 

 

Frontier IP, which specialises in commercialising university intellectual property, is pleased to announce that portfolio company Tarsis Technology ("Tarsis"), a spin out from the University of Cambridge, has entered into a collaboration agreement with one of the world's leading manufacturers of crop-protection products (the "Company").

 

The collaboration will research the use of Tarsis' patent-pending technology to deliver chemical pesticides and fungicides in a more precise and controlled way.

 

Tarsis was incorporated to develop and commercialise technology created by Dr David Fairen-Jimenez, a Royal Society University Research Fellow and University Lecturer, and his research team at the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The technology is based on particles called metal-organic frameworks and has potential for a wide range of industrial applications.

 

The Company will fund the entire research programme in return for exclusive rights to Tarsis' intellectual property for a defined set of agrochemicals. Tarsis will be paid a royalty fee for any commercially viable products that result.

 

Separately, Frontier IP has agreed to lend up to £150,000 to Tarsis to meet working capital requirements in return for equity options.

 

Tarsis Technology founder and director Dr David Fairen-Jimenez said: "We're delighted a leading player in global agrochemicals is happy to demonstrate such a strong commitment to our novel technology."

 

Frontier IP Chief Executive Neil Crabb said: "We aim to bring industry and university spin-outs together at a very early stage in the commercialisation process. In that way, we ensure new technologies meet real-world demands and needs. This agreement is yet another sign our approach is beginning to pay off."

 

 

Tarsis Technology and metal-organic frameworks:

 

Tarsis Technology specialises in developing metal-organic frameworks for the slower and more controlled delivery of active ingredients, such as agricultural chemicals. Metal-organic frameworks are particles combining organic and inorganic building blocks and are highly porous; they can adsorb a relatively large volume of an active ingredient compared to other types of particles.

 

The problem facing researchers in the past has been controlling the flow of the active ingredient from the particles - because they are porous, the ingredients leak out too quickly.

 

Tarsis Technology has developed a way of collapsing metal-organic frameworks (MOF) to lock an active ingredient inside the particle. There are many thousands of MOF particles, with different properties, including the rate at which they dissolve. Depending on which one is used, an active ingredient can be released over minutes, days or even months, or in response to climate or environmental changes.

 

 

 

 

 

 

 ENQUIRIES

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development. 

 

 

 

 

END

 

 

NRASSSFLMFASELL

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABDGDRIDBBGIX
Date   Source Headline
22nd Jul 202012:50 pmRNSHolding(s) in Company
21st Jul 20209:05 amRNSSecond Price Monitoring Extn
21st Jul 20209:00 amRNSPrice Monitoring Extension
21st Jul 20207:00 amRNSResult of Capital Raising
20th Jul 20204:37 pmRNSPrimaryBid.com Offer
20th Jul 20204:35 pmRNSProposed Capital Raising of a minimum of £2m
20th Jul 20202:00 pmRNSCambridge Raman Imaging completes £250,000 funding
14th Jul 20207:00 amRNSAquaInSilico wins grant to commercialise software
13th Jul 20207:00 amRNSPulsiv demonstrates strong progress
7th Jul 20207:00 amRNSCelerum supports development for PlanSea Solutions
6th Jul 20207:00 amRNSBosch collaboration with Fieldwork
30th Jun 20205:00 pmRNSTotal Voting Rights
23rd Jun 20207:00 amRNSThe Vaccine Group: strong COVID-19 progress
17th Jun 20207:00 amRNSCambridge & FIPP collaborate to tackle gum disease
28th May 20207:10 amRNSPortfolio news: Access to Elute's Patent Reader
28th May 20207:00 amRNSExercise of Options and Total Voting Rights
26th May 20207:00 amRNSPortfolio news – Exscientia raises $60 million
7th May 20207:00 amRNSExscientia and SRI International collaborate
1st May 20207:00 amRNSPortfolio news – Molendotech raises £425,000
15th Apr 20207:00 amRNSPortfolio news – Pulsiv Solar awarded patent
9th Apr 20207:00 amRNSPortfolio news: Alusid launches luxury Block range
6th Apr 202012:01 pmRNSHolding(s) in Company
1st Apr 20207:00 amRNSExscientia announces joint initiative re COVID-19
30th Mar 20204:40 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSElute Intelligence’s AI to back COVID-19 research
26th Mar 20207:00 amRNSPortfolio news: new portfolio company AquaInSilico
25th Mar 20207:00 amRNSUnaudited Half Year Results
19th Mar 20207:00 amRNSFrontier partners University of Lisbon competition
17th Mar 20203:15 pmRNSNotice of interim results
13th Mar 20207:00 amRNSPortfolio news – The Vaccine Group Update
12th Mar 202011:05 amRNSSecond Price Monitoring Extn
12th Mar 202011:00 amRNSPrice Monitoring Extension
19th Feb 202012:37 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSCRIL wins EUR140,000 EU Graphene Flagship funding
12th Feb 20207:00 amRNSPortfolio news - FIPP increases stake in Celerum
31st Jan 20207:00 amRNSPortfolio news - Exscientia
20th Jan 20207:00 amRNSPortfolio news - The Vaccine Group raises £680,000
16th Jan 20203:28 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSFieldwork Robotics secures first equity funding
10th Jan 20207:00 amRNSExscientia enters collaboration with Bayer AG
31st Dec 20191:00 pmRNSTotal Voting Rights
16th Dec 201910:36 amRNSExercise of Options and Issue of Equity
11th Dec 20196:03 pmRNSHolding(s) in Company
9th Dec 20193:25 pmRNSHolding(s) in Company
9th Dec 20193:21 pmRNSHolding(s) in Company
9th Dec 20192:08 pmRNSHolding(s) in Company
9th Dec 20199:46 amRNSHolding(s) in Company
9th Dec 20197:00 amRNSGrant of Options
6th Dec 20196:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.